Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

SELL
$0.43 - $0.9 $1,409 - $2,951
-3,279 Reduced 19.81%
13,273 $6,000
Q4 2022

Feb 10, 2023

BUY
$0.42 - $18.8 $3,153 - $141,169
7,509 Added 83.04%
16,552 $11,000
Q3 2022

Nov 10, 2022

SELL
$0.58 - $18.2 $2,625 - $82,373
-4,526 Reduced 33.36%
9,043 $8,000
Q2 2022

Aug 15, 2022

SELL
$0.47 - $1.29 $1,828 - $5,019
-3,891 Reduced 22.29%
13,569 $8,000
Q1 2022

May 12, 2022

SELL
$0.96 - $1.78 $5,075 - $9,410
-5,287 Reduced 23.24%
17,460 $19,000
Q4 2021

Feb 14, 2022

SELL
$1.56 - $2.99 $9,345 - $17,913
-5,991 Reduced 20.85%
22,747 $39,000
Q3 2021

Nov 15, 2021

BUY
$2.73 - $4.13 $78,454 - $118,687
28,738 New
28,738 $88,000
Q2 2021

Aug 16, 2021

SELL
$2.18 - $4.29 $14,586 - $28,704
-6,691 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$2.69 - $5.12 $3,405 - $6,481
1,266 Added 23.34%
6,691 $19,000
Q4 2020

Feb 16, 2021

SELL
$2.25 - $7.12 $42,693 - $135,102
-18,975 Reduced 77.77%
5,425 $17,000
Q3 2020

Nov 16, 2020

BUY
$3.46 - $8.39 $66,497 - $161,247
19,219 Added 370.95%
24,400 $148,000
Q2 2020

Aug 13, 2020

BUY
$2.37 - $7.14 $5,337 - $16,079
2,252 Added 76.89%
5,181 $31,000
Q1 2020

May 15, 2020

BUY
$2.46 - $5.84 $7,205 - $17,105
2,929 New
2,929 $8,000
Q4 2019

Feb 07, 2020

SELL
$1.8 - $13.43 $6,809 - $50,805
-3,783 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$8.12 - $14.54 $11,018 - $19,730
1,357 Added 55.94%
3,783 $46,000
Q2 2019

Aug 13, 2019

BUY
$9.6 - $22.85 $23,289 - $55,434
2,426 New
2,426 $28,000

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0

About Cyclerion Therapeutics, Inc.


  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $139M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.